Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Pharmacokinetics and Safety of MR19A13A in Pediatric Surgical Patients
jRCT2051220112Phase 2Completed
- Sponsor
- Maruishi Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midazolam, sponsored by Maruishi Pharmaceutical Co., Ltd. Primary endpoints: Plasma concentration of unchanged MR19A13A and its metabolites, Pharmacokinetic parameters of MR19A13A and its metabolites and 5 more. Started Jan 2023; status: completed.
02
Drugs
midazolam
Beyond the preview
Go deeper on jRCT2051220112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220112.